Sort
10,766 grants matching “checkpoint inhibitor”
Targeting myeloid suppression to enhance anti-tumor immunity in breast cancer
$579,770Evanthia Theodosiou Roussos Torres · University Of Southern California · R01 · FY2023 · CA
Analyses of human T regulatory cells
$579,726Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Project 1: Transgenic TCR-mediated tumor therapy
$579,552Philip D Greenberg · University Of Washington · P01 · FY2023 · CA
G alpha-q/11 Signaling and Inhibition in Ocular Melanoma
$579,510Kendall Jay Blumer · Washington University · R01 · FY2021 · CA
Targeting the Immune System in Mouse Models of Lung Adenocarcinoma
$579,271Katerina Abigail Politi · Yale University · R01 · FY2017 · CA
Homologous recombination deficiency and beyond in pancreatic cancer: evaluating the regulators of response to pembrolizumab and olaparib (POLAR) from the immune and genomic perspectives
$579,257Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research · P50 · FY2024 · CA
HIFU-immunotherapy in pancreatic cancer
$579,183Katherine W Ferrara · Stanford University · R01 · FY2024 · CA
In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted TGFb therapy for cancer patients
$578,977Dori A Thomas-Karyat · Synthis Therapeutics, Inc. · R44 · FY2024 · CA
Delineating Functional Immunity via Image-Guided PET
$578,749Nerissa Therese Viola · Wayne State University · R37 · FY2023 · CA
Escape from CAR T surveillance through lineage plasticity
$578,670Patricia A Ernst · University Of Colorado Denver · R01 · FY2022 · CA
Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis
$578,640Efstathios Karathanasis · Case Western Reserve University · R01 · FY2022 · CA
G alpha-q/11 Signaling and Inhibition in Ocular Melanoma
$578,437Kendall Jay Blumer · Washington University · R01 · FY2020 · CA
Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC
$578,421Raghuraman Kannan · University Of Missouri-Columbia · R01 · FY2023 · CA
(PQ6) Mesenchymal stem cell based and immunocompetent mouse models of HIV/AIDS KSHV-driven sarcomagenesis
$578,253Enrique A Mesri · University Of Miami School Of Medicine · R01 · FY2021 · CA
Elucidating the Immune Suppressive Mechanism of SIGLEC-15 in the Tumor Microenvironment
$578,201Jun Wang · New York University School Of Medicine · R01 · FY2025 · CA
Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis
$578,041Efstathios Karathanasis · Case Western Reserve University · R01 · FY2023 · CA
Immunotherapeutic responses to neoantigens in head and neck cancer
$578,036Ravindra Uppaluri · Dana-Farber Cancer Inst · R01 · FY2019 · DE
Immunotherapeutic responses to neoantigens in head and neck cancer
$578,036Ravindra Uppaluri · Dana-Farber Cancer Inst · R01 · FY2020 · DE
Immunotherapeutic responses to neoantigens in head and neck cancer
$578,036Ravindra Uppaluri · Dana-Farber Cancer Inst · R01 · FY2021 · DE
Biomarkers of Response to Immuno-chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood Assays
$577,989Stephen R. Bowen · University Of Washington · R01 · FY2024 · CA
Elucidating Mechanism of Immune Evasion in Head and Neck Cancers
$577,934Jing Hong Wang · University Of Colorado Denver · R01 · FY2019 · DE
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma
$577,925Chun Li · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Overcoming tumor-intrinsic mechanisms of immune evasion to boost systemic response to radiotherapy
$577,818Fabrice Lucien-Matteoni · Mayo Clinic Rochester · R01 · FY2025 · CA
Overcoming tumor-intrinsic mechanisms of immune evasion to boost systemic response to radiotherapy
$577,818Fabrice Lucien-Matteoni · Mayo Clinic Rochester · R01 · FY2024 · CA
Targeting SEC61 complex to overcome resistance to immunotherapy in GBM
$577,634Irina V Balyasnikova · Northwestern University At Chicago · R01 · FY2025 · CA